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We evaluated the artus RealArt Parvovirus B19 LC PCR reagent (artus biotech USA, San Francisco, Calif.)
for real-time PCR detection of parvovirus B19 DNA by retesting 71 specimens previously submitted to our
laboratory. The artus assay, which produces a quantitative result and provides an internal PCR control,
appeared to be slightly more sensitive than our conventional qualitative PCR assay.
Human parvovirus B19 is a small-DNA virus of the family
Parvoviridae that infects red blood cell precursors in the bone
marrow. The virus is spread by the respiratory route, primarily
during childhood, when it most commonly causes a febrile rash
illness called erythema infectiosum, or fifth disease (2, 3). In
the normal host, the disease is generally mild, with recovery
being the rule. Infection of patients with underlying conditions
may be more severe. Infected individuals with diseases short-
ening red blood cell life spans, such as sickle cell disease, may
develop an aplastic crisis requiring red cell transfusions (9).
Immunocompromised individuals who are unable to mount an
antibody response to the virus can develop persistent infection
with resulting chronic anemia (8). In these cases, administra-
tion of intravenous human immunoglobulin can reduce viremia
and ameliorate the anemia (7, 11). B19 virus can also cross the
placenta, resulting in fetal hydrops and spontaneous abortion
(1, 5).
Laboratory diagnosis of parvovirus infection relies primarily
upon serological methods to demonstrate an antibody re-
sponse. In cases of individuals who cannot mount an antibody
response, PCR-based methods to detect parvovirus DNA are
used. For the past 10 years, our laboratory has offered a con-
ventional PCR assay for detection of parvovirus DNA. Re-
cently, a commercial assay utilizing real-time detection of par-
vovirus DNA using the LightCycler has become available.
Because this assay offers the potential benefits of a quantitative
result, an internal control of assay performance, labor savings,
and decreased time to results, we carried out a comparison of
this kit and our conventional PCR assay.
The artus RealArt Parvo B19 LC PCR assay, sold as an
analyte-specific reagent, provides all the reagents needed to
amplify a specific region of the parvovirus B19 genome and an
internal control consisting of a second heterologous target.
The internal control is detected in a different fluorimeter chan-
nel from the B19 target and can be used to identify the pres-
ence of PCR inhibitors or as a DNA isolation control. The
artus assay was used to retest 71 specimens from 39 patients
submitted to our laboratory over the past 3 years to rule out
the presence of parvovirus B19 DNA. Specimens included 63
serum or plasma specimens, 4 cerebrospinal fluid (CSF) spec-
imens, 2 bone marrow specimens, 1 amniotic fluid specimen,
and 1 cord blood specimen. DNA was extracted at the time of
submission by using either the manual QIAGEN Mini kit or
the automated MagNA Pure method, using the total nucleic
acid kit, and the extracts were stored at 70°C prior to retest-
ing. The artus assay was used according to the manufacturer’s
instructions. Because the assay can be used to produce either
quantitative or qualitative results, we tested some specimens
qualitatively and others quantitatively. Briefly, 5 l of extracted
DNA was added to the appropriate LightCycler capillary con-
taining reaction mix consisting of primers and probes specific
for parvovirus B19 and the internal control, Taq enzyme, mag-
nesium ions, nucleotide triphosphates, internal control target,
and buffer. Each run contained at least one negative control
consisting of 5 l of water. For the assays run quantitatively,
the full set of five standards served as the positive controls and
results were expressed in international units (10) per milliliter
of blood. For assays run qualitatively, a single positive control
consisting of the 10-IU/l standard was included.
For the conventional assay, testing had been performed pre-
viously using primers reported by Koch and Adler (6) that
amplify a 699-bp fragment of the VP1 gene. Briefly, 10 l of
specimen was added to 90 l of reaction mixture composed of
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TABLE 1. Comparison of artus assay with conventional PCR for







Serum/plasmac 47 Positive 46 1*
17 Negative 2** 15
CSF 3 Positive 3 0
1 Negative 0 1
Bone marrow 1 Positive 0 1*
1 Negative 0 1
Amniotic fluid 1 Positive 1 0
a SLCH, St. Louis Children’s Hospital.
b POS, positive; NEG, negative; *, negative when retested by the SLCH lab-
oratory assay; **, no change in result when retested by both assays.




 April 6, 2014 by W






1 Stratagene Opti-Primer buffer no. 2, 100 pmol (each)
primer, 200 M (each) deoxynucleoside triphosphate, 0.2%
dimethyl sulfoxide, and 2 U of Perkin-Elmer AmpliTaq Taq
polymerase. Cycling was performed in a Perkin-Elmer 9600
thermocycler with the following program: 94°C for 3 min; then,
40 cycles of 94°C for 20 s; 50°C for 15 s; 72°C for 20 s; and last,
72°C for 2 min. Following cycling, 18 l of product was ana-
lyzed using agarose gel electrophoresis.
The specimens included 52 reported previously as positive
and 19 reported previously as negative. Testing with the artus
assay produced results that agreed with the previous results in
67 (94%) cases (Table 1). All specimens testing negative for
the presence of parvovirus DNA produced amplification with
the internal control, indicating a lack of PCR inhibitors. The
four discrepant specimens included two reported originally as
positive and two reported as negative. To resolve the discrep-
ancies, the four specimens were retested by both assays. For
the two specimens initially negative by the conventional assay
and positive by the artus test, retesting produced results iden-
tical to the initial results for both assays. One specimen pro-
duced an initial artus result of 134 IU/ml, suggesting that a low
titer of virus was the reason for the negative results in the
conventional assay. Likewise, the second discrepant specimen
had a relatively low titer of 79,000 IU/ml and a negative con-
ventional result, although seven other specimens with approx-
imately equal or lower titers were positive in the conventional
assay. Because both specimens were from patients with chronic
parvovirus infections who had multiple positive specimens, it is
likely that the artus results were true positives. Although false-
positive results of the initial conventional PCR assay cannot be
ruled out, for the remaining two discrepant specimens, retest-
ing resulted in negative results by both assays for specimens
originally reported as positive by the conventional assay. The
lack of inhibition noted in these specimens suggested degra-
FIG. 1. Fluctuations in the levels of parvovirus B19 viremia with time in three patients with persistent parvovirus infections. Day 0 represents
the first day that specimens were obtained for each patient. The level of viremia is expressed in international units per milliliter of blood as
determined by the artus assay. The  and  symbols in each panel represent the conventional PCR qualitative result for each specimen. Each
asterisk in panel A represents the quantitative level of B19 DNA in cerebrospinal fluid specimens obtained from that patient.
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dation of a low titer of B19 DNA during storage. After retest-
ing, the artus assay agreed with the conventional PCR for 69
(97%) of specimens.
The 39 positive specimens tested quantitatively yielded titers
from 1.3  102 to 4.4  1011 IU/ml of original specimen.
Although in most cases a qualitative parvovirus PCR result is
sufficient, with chronic infection it may be desirable to produce
a quantitative result to assess responses to the administration
of human immunoglobulin. Quantitative results from multiple
specimens obtained over time on three separate patients with
chronic parvovirus infections are shown in Fig. 1. The apparent
changes in viral titers noted in these specimens likely represent
responses to the administration of human immunoglobulin,
although we could not confirm this because specimens had
been stripped of identifiers before testing.
In addition to blood specimens, we also tested an amniotic
fluid specimen and four CSF specimens. The amniotic fluid
and the companion blood specimen from the same patient
were both positive, confirming infection of the fetus, although
the amniotic fluid contained a titer of virus close to 4 logs lower
than that of the blood. Interestingly, one of the patients with
chronic parvovirus infection also had CSF specimens submit-
ted that were positive for the presence of parvovirus B19 DNA
(Fig. 1A). Neurological complications have been associated
with parvovirus B19 infections, but the mechanism of these
effects is unclear. In some cases, B19 DNA has been found in
the CSF of patients with encephalitis or meningitis (4).
In summary, the artus assay was simple to use, provided
rapid results, included an internal control of the PCR, and gave
the option of producing quantitative results. Our results indi-
cated that the artus assay was more sensitive than the conven-
tional assay we now use and was able to accurately detect B19
DNA in a variety of specimens. The inclusion of an amplifica-
tion control was particularly useful for ruling out PCR inhib-
itors and would presumably help satisfy laboratory regulatory
requirements for amplification controls. For laboratories using
the LightCycler, the artus parvovirus assay represents a useful
option for detection of parvovirus DNA.
REFERENCES
1. Anand, A., E. S. Brown, J. P. Clewley, and B. J. Cohen. 1987. Human
parvovirus infection in pregnancy and hydrops fetalis. N. Engl. J. Med.
31:183–186.
2. Anderson, M. J., P. G. Higgins, L. R. Davis, J. S. Willman, S. E. Jones, I. M.
Kid, J. R. Pattison, and D. A. Tyrell. 1985. Experimental parvoviral infection
in humans. J. Infect. Dis. 152:257–265.
3. Anderson, M. J., S. E. Jones, S. P. Fisher-Hoch, E. Lewis, S. M. Hall, C. L. R.
Bartlett, B. J. Cohen, P. P. Mortimer, and M. S. Pereira. 1983. Human
parvovirus, the cause of erythema infectiosum (fifth disease)? Lancet i:1378.
4. Barah, F., P. J. Vallely, G. M. Cleator, and J. R. Kerr. 2003. Neurological
manifestations of human parvovirus B19 infection. Rev. Med. Virol. 13:185–
199.
5. Brown, T., A. Anand, L. D. Ritchie, J. P. Clewley, and T. M. Reid. 1984.
Intrauterine parvovirus infection associated with hydrops fetalis. Lancet ii:
1033–1034.
6. Koch, W. C., and S. P. Adler. 1990. Detection of human parvovirus B19 DNA
by using the polymerase chain reaction. J. Clin. Microbiol. 28:65–69.
7. Kurtzman, G., N. Frickhofen, J. Kimball, D. W. Jenkins, A. W. Nienhuis,
and N. S. Young. 1989. Pure red-cell aplasia of 10 years duration due to
persistent parvovirus B19 infection and its cure with immunoglobulin ther-
apy. N. Engl. J. Med. 321:519–523.
8. Kurtzman, G., K. Ozawa, B. Cohen, G. Hanson, R. Oseas, and N. S. Young.
1987. Chronic bone marrow failure due to persistent B19 parvovirus infec-
tion. N. Engl. J. Med. 317:287–294.
9. Pattison, J. R., S. E. Jones, J. Hodgson, L. R. Davis, J. M. White, J. E.
Stroud, and L. Murtaza. 1981. Parvovirus infections and hypoplastic crisis in
sickle-cell anaemia. Lancet i:664–665.
10. Saldanha, J. N. Lelie, M. W. Yu, and A. Heath. 2002. Establishment of the
first World Health Organization International Standard for human parvovi-
rus B19 DNA nucleic acid amplification techniques. Vox Sanguinis 82:24–31.
11. Young, N. S. 1996. Parvovirus infection and its treatment. Clin. Exp. Immu-
nol. 104(Suppl. 1):26–30.
3328 NOTES J. CLIN. MICROBIOL.
 o
n
 April 6, 2014 by W
ashington University in St. Louis
http://jcm.asm.org/
D
ow
nloaded from
 
